Trial Profile
A 1-week, multi-center, randomized, double-blind, double-dummy, active-controlled, parallel trial comparing lumiracoxib (400 mg once daily) in patients with acute flares of gout, using indomethacin (50 mg three times a day)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lumiracoxib (Primary) ; Indometacin
- Indications Gout; Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Novartis
- 22 Dec 2005 New trial record.